Home
APLS
APLS News

Latest Apellis Pharmaceuticals Inc. (APLS) News on December 22, 2024

MT Newswires

5 days ago

Goldman Sachs Downgrades Apellis Pharmaceuticals to Neutral From Buy, $36 Price Target

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?

Zacks

10 days ago

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?

Should You Hold Apellis Pharmaceuticals (APLS)?

Insider Monkey

10 days ago

Should You Hold Apellis Pharmaceuticals (APLS)?

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

16 days ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Zacks

16 days ago

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?

Zacks

17 days ago

Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.

18 days ago

Exploring Three High Growth Tech Stocks in the United States

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire

25 days ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

GlobeNewswire

a month ago

Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference

Apellis price target lowered to $30 from $43 at Wells Fargo

TipRanks

a month ago

Apellis price target lowered to $30 from $43 at Wells Fargo

Apellis price target lowered to $47 from $61 at BofA

TipRanks

a month ago

Apellis price target lowered to $47 from $61 at BofA

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

Zacks

2 months ago

Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y

MT Newswires

2 months ago

RBC Capital Trims Price Target on Apellis Pharmaceuticals to $24 From $25, Maintains Sector Perform Rating

MT Newswires

2 months ago

Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $40 From $65, Maintains Outperform Rating

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

GuruFocus.com

2 months ago

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

Motley Fool

2 months ago

Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $25 From $27, Maintains Neutral Rating

Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks

2 months ago

Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say

Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales

Investor's Business Daily

2 months ago

Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales

High Growth Tech Stocks to Watch in November 2024

Simply Wall St.

2 months ago

High Growth Tech Stocks to Watch in November 2024

MT Newswires

2 months ago

Apellis Pharmaceuticals Q3 Loss Narrows, Revenue Gains -- Shares Fall Pre-Bell

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates

Zacks

2 months ago

Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

GlobeNewswire

2 months ago

Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For

GuruFocus.com

2 months ago

Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

2 months ago

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know

Zacks

2 months ago

Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

Motley Fool

2 months ago

1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst

Apellis, Sobi announced results from Phase 3 VALIANT study

TipRanks

2 months ago

Apellis, Sobi announced results from Phase 3 VALIANT study

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

GlobeNewswire

2 months ago

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

MT Newswires

2 months ago

Mizuho Trims Price Target on Apellis Pharmaceuticals to $38 From $39, Keeps Neutral Rating

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

GlobeNewswire

2 months ago

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

Benzinga

2 months ago

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch

MT Newswires

2 months ago

William Blair Initiates Apellis Pharmaceuticals at Outperform

MT Newswires

2 months ago

Scotiabank Initiates Apellis Pharmaceuticals at Sector Perform With $35 Price Target

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

GlobeNewswire

2 months ago

Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Should You Hold Apellis Pharmaceuticals (APLS)?

Insider Monkey

3 months ago

Should You Hold Apellis Pharmaceuticals (APLS)?

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

GlobeNewswire

3 months ago

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU

Zacks

3 months ago

Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

Investor's Business Daily

3 months ago

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

MT Newswires

3 months ago

Sector Update: Health Care

MT Newswires

3 months ago

Apellis European Rejection for Vision Treatment Dents Revenue Growth, Stock Performance, Wedbush Says

MT Newswires

3 months ago

--Wedbush Cuts Price Target on Apellis Pharmaceuticals to $35 From $41, Maintains Neutral Rating; Shares Fall

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Premarket Friday

MT Newswires

3 months ago

Sector Update: Health Care

Apellis eye drug again turned back in Europe

BioPharma Dive

3 months ago

Apellis eye drug again turned back in Europe

MT Newswires

3 months ago

Apellis Pharmaceuticals Gets Reaffirmed Negative CHMP Opinion on Pegcetacoplan for Geographic Atrophy

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

GlobeNewswire

3 months ago

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

MT Newswires

3 months ago

Apellis Pharmaceuticals Insider Sold Shares Worth $1,340,597, According to a Recent SEC Filing

Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds’ Top Biotech Stock Picks

Insider Monkey

3 months ago

Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds’ Top Biotech Stock Picks

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?

Zacks

4 months ago

Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?

Exploring 3 High Growth Tech Stocks in the United States

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks in the United States

Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?

Zacks

4 months ago

Acadia (ACAD) Up 10% Since Last Earnings Report: Can It Continue?

Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Insider Monkey

4 months ago

Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?

Zacks

4 months ago

Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire

4 months ago

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

MT Newswires

4 months ago

UBS Cuts Price Target on Apellis Pharmaceuticals to $83 From $85, Maintains Buy Rating

MT Newswires

4 months ago

Wedbush Adjusts Apellis Pharmaceuticals' PT to $41 From $38, Keeps Neutral Rating

MT Newswires

4 months ago

Mizuho Adjusts Apellis Pharmaceuticals' PT to $42 From $40, Keeps Neutral Rating

Sobi and Apellis report positive topline results from Phase III pegcetacoplan study

Clinical Trials Arena

4 months ago

Sobi and Apellis report positive topline results from Phase III pegcetacoplan study

Apellis plans FDA filing after drug success in kidney trial

BioPharma Dive

4 months ago

Apellis plans FDA filing after drug success in kidney trial

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

PR Newswire

4 months ago

Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

GlobeNewswire

4 months ago

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

5 months ago

Mizuho Adjusts Apellis Pharmaceuticals' PT to $40 From $49, Keeps Neutral Rating

Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues

Zacks

5 months ago

Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues

MT Newswires

5 months ago

Apellis Pharmaceuticals Q2 Loss Narrows as Revenue Increases

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics

Zacks

5 months ago

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics

Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates

Zacks

5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

When Will Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Breakeven?

Simply Wall St.

5 months ago

When Will Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Breakeven?

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

5 months ago

Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

GlobeNewswire

5 months ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe

Zacks

6 months ago

Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

Zacks

6 months ago

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

MT Newswires

6 months ago

Sector Update: Health Care Stocks Edge Higher in Afternoon Trading

MT Newswires

6 months ago

Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $49 From $52, Maintains Neutral Rating

MT Newswires

6 months ago

Update: Apellis Pharmaceuticals Shares Fall After Announcing Plan to Seek Re-Examination of Negative CHMP Opinion on Pegcetacoplan for Geographic Atrophy

MT Newswires

6 months ago

Apellis Pharmaceuticals to Seek Re-Examination of Negative CHMP Opinion on Pegcetacoplan for Geographic Atrophy

MT Newswires

6 months ago

--Wedbush Cuts Price Target on Apellis Pharmaceuticals to $40 From $50, Maintains Neutral Rating

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

GlobeNewswire

6 months ago

Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU

MT Newswires

6 months ago

Apellis Pharmaceuticals Insider Sold Shares Worth $1,451,835, According to a Recent SEC Filing

Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week

Simply Wall St.

6 months ago

Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

6 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

6 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

6 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

6 months ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

6 months ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

6 months ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

6 months ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

6 months ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

Zacks

6 months ago

Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

GlobeNewswire

6 months ago

SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)

Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?

Zacks

7 months ago

Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

7 months ago

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

MT Newswires

7 months ago

Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target

Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data

Zacks

7 months ago

Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data

Apellis and Sobi report data from Phase II C3 glomerulopathy trial

Clinical Trials Arena

7 months ago

Apellis and Sobi report data from Phase II C3 glomerulopathy trial

Share on Social Networks: